Shakira sells ABT 40.9: Morgan Stanley Sees Growth Acceleration As Key To Thesis For Abbott Laboratories
In a report published Monday, Morgan Stanley analyst David R. Lewis reiterated an Overweight rating and $45.00 price target on Abbott Laboratories (NYSE: ABT). In the report, Morgan Stanley noted, âAbbott is a unique healthcare asset, with high exposure ... ...
45 people liked this
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home